ATE180976T1 - Insizierbare lecithin gel - Google Patents
Insizierbare lecithin gelInfo
- Publication number
- ATE180976T1 ATE180976T1 AT93921914T AT93921914T ATE180976T1 AT E180976 T1 ATE180976 T1 AT E180976T1 AT 93921914 T AT93921914 T AT 93921914T AT 93921914 T AT93921914 T AT 93921914T AT E180976 T1 ATE180976 T1 AT E180976T1
- Authority
- AT
- Austria
- Prior art keywords
- gel
- insizable
- active compound
- biologically active
- lecithin gel
- Prior art date
Links
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 title abstract 2
- 229940067606 lecithin Drugs 0.000 title abstract 2
- 235000010445 lecithin Nutrition 0.000 title abstract 2
- 239000000787 lecithin Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96075292A | 1992-10-14 | 1992-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE180976T1 true ATE180976T1 (de) | 1999-06-15 |
Family
ID=25503572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93921914T ATE180976T1 (de) | 1992-10-14 | 1993-10-05 | Insizierbare lecithin gel |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5863549A (de) |
| EP (1) | EP0620740B1 (de) |
| JP (1) | JP2613750B2 (de) |
| CN (1) | CN1090509A (de) |
| AT (1) | ATE180976T1 (de) |
| AU (1) | AU672441B2 (de) |
| CA (1) | CA2125784A1 (de) |
| DE (1) | DE69325256T2 (de) |
| ES (1) | ES2133413T3 (de) |
| IL (1) | IL107207A0 (de) |
| IS (1) | IS4083A (de) |
| LV (1) | LV10180A (de) |
| MX (1) | MX9306239A (de) |
| NZ (1) | NZ256413A (de) |
| RU (1) | RU94033520A (de) |
| SI (1) | SI9300468A (de) |
| UY (1) | UY23665A1 (de) |
| WO (1) | WO1994008623A1 (de) |
| ZA (1) | ZA937459B (de) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US6379631B1 (en) | 1996-06-28 | 2002-04-30 | Johnson & Johnson Medical, Inc. | Instrument sterilization container formed of a liquid crystal polymer |
| US6264902B1 (en) | 1996-06-28 | 2001-07-24 | Johnson & Johnson Medical, Inc. | Instrument sterilization container having an improved latching mechanism |
| AU4841599A (en) * | 1998-06-29 | 2000-01-17 | Pharmaceuticals Applications Asociates, Llc | Methods and transdermal compositions for pain relief |
| US8052982B2 (en) | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
| ES2389627T3 (es) * | 1998-07-20 | 2012-10-29 | Virbac (Australia) Pty Ltd | Formulación para bioimplantes |
| AU755443C (en) * | 1998-07-20 | 2006-08-17 | Virbac (Australia) Pty Limited | Bioimplant formulation |
| EP1064934A1 (de) * | 1999-06-30 | 2001-01-03 | Applied Research Systems ARS Holding N.V. | Gefriergetrocknete GRF-enthaltende Arzneimittel |
| US6191121B1 (en) * | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
| US6979459B1 (en) | 2000-04-06 | 2005-12-27 | Perricone Nicholas V | Treatment of skin damage using polyenylphosphatidycholine |
| US6932963B2 (en) | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
| US20020106406A1 (en) * | 2000-12-08 | 2002-08-08 | Mchugh Anthony J. | Crystallizable/non-crystallizable polymer composites |
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| EP1480618B1 (de) | 2002-03-04 | 2009-06-03 | Ipsen Pharma | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid |
| JP2005528352A (ja) | 2002-03-12 | 2005-09-22 | エチファルム | 生体活性物質の持続的放出に用いるためのゲル化特性を有する組成物 |
| KR100906547B1 (ko) | 2002-03-12 | 2009-07-07 | 에띠빠흠 | 생활성 물질의 지속적 전달을 위한 겔화 특성을 갖는 조성물 |
| US20040025791A1 (en) * | 2002-08-09 | 2004-02-12 | Applied Materials, Inc. | Etch chamber with dual frequency biasing sources and a single frequency plasma generating source |
| FR2868704B1 (fr) * | 2004-04-07 | 2007-09-14 | Ethypharm Sa | Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires |
| WO2006002050A1 (en) * | 2004-06-15 | 2006-01-05 | Encore Therapeutics, Inc. | Phospholipid compositions and methods for their preparation and use |
| US7858115B2 (en) * | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| US20080095849A1 (en) * | 2005-04-25 | 2008-04-24 | Amgen Inc. | Peptide sustained release compositions and uses thereof |
| US7695633B2 (en) * | 2005-10-18 | 2010-04-13 | Applied Materials, Inc. | Independent control of ion density, ion energy distribution and ion dissociation in a plasma reactor |
| CU23432B6 (es) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
| PL1787658T3 (pl) | 2005-11-10 | 2012-08-31 | Italfarmaco Spa | Formulacje o przedłużonym uwalnianiu analogów somatostatyny będących inhibitorami hormonu wzrostu |
| US8017159B2 (en) * | 2005-11-16 | 2011-09-13 | Idexx Laboratories, Inc. | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same |
| US20070246443A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma process for controlling plasma ion dissociation |
| US7645357B2 (en) * | 2006-04-24 | 2010-01-12 | Applied Materials, Inc. | Plasma reactor apparatus with a VHF capacitively coupled plasma source of variable frequency |
| US20070245958A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source for controlling ion radial distribution |
| US20070246162A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with an inductive plasma source and a VHF capacitively coupled plasma source with variable frequency |
| US20070246163A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with independent capacitive and inductive plasma sources |
| US7727413B2 (en) * | 2006-04-24 | 2010-06-01 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source to control plasma ion density |
| US20070245961A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source for controlling plasma ion dissociation |
| US7780864B2 (en) * | 2006-04-24 | 2010-08-24 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion radial distribution |
| US20070246161A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with a toroidal plasma source and a VHF capacitively coupled plasma source with variable frequency |
| US20070245960A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion density |
| US7403325B2 (en) * | 2006-05-19 | 2008-07-22 | Xerox Corporation | Electrophoretic display device |
| EP2197497B1 (de) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Verwendung von liposomen in einem träger mit einer kontinuierlichen hydrophoben phase zur abgabe von polynucleotiden in vivo |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| TWI442932B (zh) * | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| WO2009114959A1 (zh) * | 2008-03-20 | 2009-09-24 | 中国人民解放军军事医学科学院毒物药物研究所 | 可注射用缓释药物制剂及其制备方法 |
| CN102056622B (zh) * | 2008-06-05 | 2016-04-06 | 免疫疫苗技术有限公司 | 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物 |
| EP2424503B1 (de) * | 2009-05-01 | 2017-07-05 | Ferring BV | Zusammensetzung zur Behandlung von Prostatakrebs |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| WO2011075623A1 (en) | 2009-12-18 | 2011-06-23 | Latitude Pharmaceuticals, Inc. | One - phase gel compos ition compri s ing phos pholi pids |
| CA2809022C (en) | 2010-08-20 | 2017-01-03 | Dr. Reddy`S Laboratories, Inc. | Phospholipid depot |
| BR112013009743A2 (pt) * | 2010-10-22 | 2016-07-19 | Reddys Lab Inc Dr | uso de deposito de fosfolipidio viscoso estavel ao armazenamento para tratar ferimentos |
| EP2447276A1 (de) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Verfahren zur Herstellung von Degarelix und seinen Zwischenprodukten |
| PL2632934T3 (pl) | 2010-10-27 | 2017-06-30 | Ferring B.V. | Sposób wytwarzania degareliksu i jego związków pośrednich |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| KR20140041686A (ko) * | 2011-06-09 | 2014-04-04 | 아밀린 파마슈티칼스, 엘엘씨. | 겔 조성물 |
| BR112014007927B1 (pt) | 2011-10-06 | 2021-04-13 | Immunovaccine Technologies Inc | Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições |
| IN2014MN02214A (de) | 2012-05-10 | 2015-07-17 | Painreform Ltd | |
| AR092840A1 (es) | 2012-06-01 | 2015-05-06 | Ferring Bv | Elaboracion de degarelix |
| KR102227966B1 (ko) * | 2019-06-26 | 2021-03-16 | 주식회사 엠이티라이프사이언스 | 비활성 폴리펩타이드 ｔｒｐ의 약제학적 제형 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4377567A (en) * | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
| US4252793A (en) * | 1979-06-18 | 1981-02-24 | American Lecithin Company | Injectable lecithin preparation |
| US4297353A (en) * | 1980-08-04 | 1981-10-27 | Sandoz, Inc. | Non-irritating injectable dosage forms |
| US4578391A (en) * | 1982-01-20 | 1986-03-25 | Yamanouchi Pharmaceutical Co., Ltd. | Oily compositions of antitumor drugs |
| FR2562421B1 (fr) * | 1984-04-09 | 1989-02-17 | Sandoz Sa | Perfectionnements a la therapie par l'interleukine |
| US4761288A (en) * | 1984-09-24 | 1988-08-02 | Mezei Associates Limited | Multiphase liposomal drug delivery system |
| GB8603621D0 (en) * | 1986-02-14 | 1986-03-19 | Habib N | Modifying lipid structure of cell membranes |
| US5084269A (en) * | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
| NZ222907A (en) * | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| CH681427A5 (de) * | 1987-07-01 | 1993-03-31 | Zambon Spa | |
| JP2643217B2 (ja) * | 1988-01-22 | 1997-08-20 | エーザイ株式会社 | 脂溶性物質水性液 |
| US5124151A (en) * | 1990-08-07 | 1992-06-23 | Mediventures Inc. | Drug delivery by injection with thermo-irreversible gels |
| US5143731A (en) * | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| US5505877A (en) * | 1991-10-15 | 1996-04-09 | Krivohlavek; Dennis | Making multiple phase emulsion or gel |
| DE4201527A1 (de) * | 1992-01-21 | 1993-07-22 | Knoll Ag | Lecithinhaltige loesungen mit levemopamil |
| US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| US5660854A (en) * | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
-
1993
- 1993-09-08 SI SI9300468A patent/SI9300468A/sl unknown
- 1993-10-05 EP EP93921914A patent/EP0620740B1/de not_active Expired - Lifetime
- 1993-10-05 AU AU51110/93A patent/AU672441B2/en not_active Ceased
- 1993-10-05 RU RU94033520/14A patent/RU94033520A/ru unknown
- 1993-10-05 DE DE69325256T patent/DE69325256T2/de not_active Expired - Fee Related
- 1993-10-05 WO PCT/EP1993/002711 patent/WO1994008623A1/en active IP Right Grant
- 1993-10-05 AT AT93921914T patent/ATE180976T1/de not_active IP Right Cessation
- 1993-10-05 JP JP6509578A patent/JP2613750B2/ja not_active Expired - Fee Related
- 1993-10-05 NZ NZ256413A patent/NZ256413A/en unknown
- 1993-10-05 CA CA002125784A patent/CA2125784A1/en not_active Abandoned
- 1993-10-05 ES ES93921914T patent/ES2133413T3/es not_active Expired - Lifetime
- 1993-10-06 IL IL107207A patent/IL107207A0/xx unknown
- 1993-10-07 MX MX9306239A patent/MX9306239A/es unknown
- 1993-10-07 ZA ZA937459A patent/ZA937459B/xx unknown
- 1993-10-13 CN CN93119112A patent/CN1090509A/zh active Pending
- 1993-10-13 LV LV931150A patent/LV10180A/xx unknown
- 1993-10-13 IS IS4083A patent/IS4083A/is unknown
- 1993-10-13 UY UY23665A patent/UY23665A1/es unknown
-
1996
- 1996-08-22 US US08/701,274 patent/US5863549A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06511263A (ja) | 1994-12-15 |
| EP0620740B1 (de) | 1999-06-09 |
| DE69325256D1 (de) | 1999-07-15 |
| WO1994008623A1 (en) | 1994-04-28 |
| UY23665A1 (es) | 1994-04-06 |
| JP2613750B2 (ja) | 1997-05-28 |
| US5863549A (en) | 1999-01-26 |
| ES2133413T3 (es) | 1999-09-16 |
| RU94033520A (ru) | 1996-11-10 |
| IL107207A0 (en) | 1994-01-25 |
| AU5111093A (en) | 1994-05-09 |
| EP0620740A1 (de) | 1994-10-26 |
| MX9306239A (es) | 1994-06-30 |
| IS4083A (is) | 1994-04-15 |
| LV10180A (lv) | 1994-10-20 |
| CA2125784A1 (en) | 1994-04-28 |
| NZ256413A (en) | 1996-07-26 |
| CN1090509A (zh) | 1994-08-10 |
| ZA937459B (en) | 1994-04-14 |
| SI9300468A (en) | 1994-06-30 |
| DE69325256T2 (de) | 1999-12-16 |
| AU672441B2 (en) | 1996-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69325256T2 (de) | Insizierbare lecithin gel | |
| DK1137762T3 (da) | Behandling af Pompes sygdom | |
| DK0696205T3 (da) | Anvendelse af neuro-afledte fetale cellelinier til transplantationsterapi | |
| DE3382458D1 (de) | Haarwuchsmittel. | |
| DE3888064D1 (de) | Niederfrequenz-Elektrotherapiegerät. | |
| ATE338813T1 (de) | Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen | |
| PT950057E (pt) | Enantiomeros de 3-piridilo e sua utilizacao como analgesicos | |
| DE69814394D1 (de) | Verwendung von levobupivacain | |
| ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
| ATE230609T1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| ATE126061T1 (de) | Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum. | |
| FR2616831B1 (fr) | Structure de type alveolaire pour l'enterrement de restes humains | |
| MY104521A (en) | Treatment of depression. | |
| DE69313261D1 (de) | Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS | |
| GR3006674T3 (de) | ||
| ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| ATE147978T1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
| EP0301449A3 (en) | Enantiomers of propafenone-containing therapeutic agents | |
| DE3374066D1 (en) | N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor | |
| ATE248218T1 (de) | Humane hypertrophe chrondrozyten zelllinien | |
| DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine | |
| SE9003140D0 (sv) | Method and composition for treatment of heart diseases | |
| UA23921A (uk) | Спосіб лікування шлунково-стравохідного рефлюксу |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |